International Study on the Corporate Reputation of Pharma in 2022: have your say

For weblink, see below

For the attention of: health campaigners

We are approaching your organization, as a key health campaigner in your field in North America, to obtain your views on the reputation of pharma in 2022―whether good or bad.

This annual PatientView study is conducted entirely independently. No pharmaceutical funding is involved. Every year, PatientView funds the research itself by selling final reports to industry, to governments, and to national and international drug-regulatory bodies. Patient groups that participate in the study are given the study results for free.

About this survey: PatientView has been conducting it’s ‘Corporate Reputation of Pharma’ survey for 12 years. Each year, thousands of patient groups share with the survey their perspectives on the performance of the pharma industry, and on that of individual pharma companies, advising how the industry might better be able to serve the needs of patients.

This survey is unique in that it is independently-run. Which is why we would like to hear your opinions on the subject: whether, in 2022, pharma has met your expectations—and, if not, how might the industry, and individual pharma companies, improve at providing support and help to patients and patient groups?

How can the results of this new 2022 survey help your organization? The survey gives health campaigners a platform to raise crucial issues in patient treatment and care. Patient groups are ideally positioned to hold such valuable insights, as they network with all of the other stakeholders in the healthcare system. Most of the major (and many of the smaller) pharma companies take the results of this annual survey very seriously. They rely on the insights they gain from the survey results to build strategies around patients. Your participation in this survey is therefore important.

WEBLINK: to the survey on the ‘Corporate Reputation of Pharma in 2022’:

https://www.surveymonkey.com/r/2022-Corporate-Reputation-of-Pharma-North-America

(PLEASE WAIT A FEW SECONDS TO REACH THE ONLINE LINK)

SOME FURTHER NOTES ABOUT THE SURVEY

To thank you for participating, will send you the survey results. PatientView cannot pay fees to you for your involvement, since payment might influence feedback. However, PatientView will send you a full copy of the final results (if you wish). Publication of the series of reports resulting from the survey is due to begin in April 2023. Included in the series are separate analyses of the opinions of patient groups from different countries and therapy areas.
How much time will it take to complete the survey? The survey will probably take about 15 minutes to complete.
Should you tell us who you are when you participate in the survey? We leave the choice up to you. Some patient groups that participate prefer to remain anonymous. The survey’s questionnaire is being carried on a specialist survey website, so allowing all responses to be completely anonymous (unless you wish otherwise). Other patient groups that participate are happy for their organization’s name to be published in the final report (which also helps us improve our analyses of the amalgamate data). Whether you wish to be anonymous or attributed, please leave your contact details at the end of the survey if you wish to receive your copy of the survey results (be assured that only PatientView will get to see these contact details).
When does the survey close? The survey closes on March 1st 2023. However, to be sure we receive your response in time, we would be grateful if you could provide your feedback as soon as possible.

If you have any questions, please contact me:

Dr. Alexandra Wyke,
CEO,
PatientView,
London, UK

e-mail: alexwyke @ patient-view.com
Tel: +44-(0)7960-855-019